Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 15, p.2530-5 (2009)

Keywords:

2009, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cisplatin, Diarrhea, Etoposide, Female, Glucuronosyltransferase, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, NEUTROPENIA, P-Glycoprotein, Pharmacogenetics, Polymorphism, Single Nucleotide, Public Health Sciences Division, Risk Factors, Small Cell Lung Carcinoma

Abstract:

Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC.